Breaking News
Upgrade 0
🔮 Are you bullish or bearish on Tesla right now?
Ask WarrenAI
Close

Milestone Pharmaceuticals Inc (MIST)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Milestone Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.690 -0.030    -1.74%
10:41:10 - Real-time Cboe. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 119,313
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.690 - 1.730
Milestone Pharmaceuticals 1.690 -0.030 -1.74%

MIST Recent Sentiments

 
This page contains information on users’ sentiments for the Milestone Pharmaceuticals Inc stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Jun 02, 2025 태균 김   1.720 -1.74%
Jun 02, 2025 태균 김   1.720 -1.74%
May 09, 2025 Yusuf Savci   1.125 May 16, 2025 @ 1.208 +7.38%
Apr 22, 2025 vin ama   1.050 May 16, 2025 @ 1.220 +16.19%
Apr 21, 2025 Giuseppe Natale   0.939 May 12, 2025 @ 1.110 +18.21%
Apr 16, 2025 Giuseppe Natale   0.790 Apr 21, 2025 @ 0.939 +18.86%
Apr 05, 2025 Mohamad Rasoul   0.741 Apr 07, 2025 @ 0.691 -6.75%
Mar 31, 2025 Francesco Schifani   0.799 Apr 25, 2025 @ 1.280 +60.20%
Mar 31, 2025 Francesc Mañaricua   0.870 Mar 31, 2025 @ 0.802 -7.82%
Mar 28, 2025 Robbert Kuipers   0.855 Apr 18, 2025 @ 0.889 +3.98%
Mar 28, 2025 Robbert Kuipers   0.853 Mar 28, 2025 @ 0.850 -0.35%
Mar 27, 2025 Alex Meloncon   2.241 Mar 31, 2025 @ 0.802 -64.21%
Mar 26, 2025 Gerardo Vargas Suarez   1.980 Mar 31, 2025 @ 0.802 -59.49%
Mar 24, 2025 К А   2.055 Mar 24, 2025 @ 2.055 0.00%
Mar 20, 2025 하성 김   2.370 Mar 24, 2025 @ 2.070 -12.66%
Feb 19, 2025 vin ama   2.110 Mar 14, 2025 @ 2.170 +2.84%
Jan 06, 2025 Scott Ross   2.159 Jan 13, 2025 @ 2.000 -7.36%
Jan 03, 2025 Scott Ross   2.230 Jan 06, 2025 @ 2.250 +0.90%
Dec 17, 2024 Ni Tefe   1.800 Dec 17, 2024 @ 1.815 -0.83%
Sep 17, 2024 Ni Tefe   1.530 Sep 17, 2024 @ 1.530 0.00%
May 10, 2024 Ramiro Millán Fraile   1.695 May 13, 2024 @ 1.720 +1.47%
Apr 10, 2024 Ramiro Millán Fraile   1.730 Apr 15, 2024 @ 1.720 -0.58%
Mar 11, 2024 Suharjono SUHARJONO   1.460 Apr 05, 2024 @ 1.800 +23.29%
Jan 04, 2024 Sutrisno Adi   1.810 Jan 26, 2024 @ 1.540 -14.92%
Jan 02, 2024 Mehmet Yoldaş   1.670 Jan 26, 2024 @ 1.540 -7.78%
Dec 28, 2023 Ni Tefe   1.770 Jan 05, 2024 @ 1.805 -1.98%
Dec 28, 2023 SAN Invertex Boy   1.780 Jan 01, 2024 @ 1.670 +6.18%
Dec 28, 2023 Juan Mielgo Ayuso   1.850 Dec 30, 2023 @ 1.670 -9.73%
Dec 26, 2023 Aitor Rodríguez   2.000 Jan 05, 2024 @ 1.765 +11.75%
Sep 19, 2023 Ramiro Millán Fraile   3.110 Nov 30, 2023 @ 3.090 -0.64%
Aug 09, 2023 Arman Kala   3.560 Aug 15, 2023 @ 3.167 +11.04%
Aug 08, 2023 Robbert Kuipers   3.384 Nov 30, 2023 @ 3.090 -8.69%
Aug 08, 2023 Robbert Kuipers   3.384 Aug 08, 2023 @ 3.384 0.00%
Nov 07, 2022 Andreas Schatz   4.170 Dec 02, 2022 @ 4.940 +18.47%
Oct 17, 2022 Cruzeiro dos Santos   8.215 Oct 24, 2022 @ 5.190 +36.82%
Aug 18, 2022 Robbert Kuipers   7.300 Aug 22, 2022 @ 7.450 +2.05%
Jul 18, 2022 Miki Tashima   6.500 Aug 13, 2022 @ 7.080 +8.92%
Nov 16, 2021 종운 김   6.950 Dec 10, 2021 @ 5.850 -15.83%
May 07, 2021 Patricio Cacciacane   5.670 May 28, 2021 @ 6.050 +6.70%
Apr 05, 2021 Javier Castelo   5.850 Apr 30, 2021 @ 5.860 +0.17%
Mar 11, 2021 Resham singh chohla...   7.500 Apr 02, 2021 @ 6.050 -19.33%
Feb 12, 2021 Markus Dohr   7.960 Mar 05, 2021 @ 6.910 -13.19%
Jan 15, 2021 Diego Maroño   7.050 Jan 15, 2021 @ 0.000 0.00%
Jan 11, 2021 yusniel sanchez   7.050 Feb 05, 2021 @ 8.270 -17.30%
Oct 23, 2020 yuvraj hara   6.060 Nov 13, 2020 @ 6.330 +4.46%
Oct 22, 2020 carmine perrini   6.930 Nov 13, 2020 @ 6.330 -8.66%
Sep 03, 2020 혜민 경   7.730 Sep 25, 2020 @ 7.610 -1.55%
Aug 17, 2020 jay lo   8.900 Sep 11, 2020 @ 7.810 -12.25%
Aug 07, 2020 Yunus Acikyurek   9.420 Aug 28, 2020 @ 7.720 -18.05%
Aug 03, 2020 Jendy Almonte   8.850 Aug 28, 2020 @ 7.720 -12.77%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MIST Comments

Write your thoughts about Milestone Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Scott Ross
Scott Ross Jun 02, 2025 11:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nothing wrong with the drug. The crash down to 63 cents was the buying opportunity of a lifetime. All the dumb analysts downgraded it right at the bottom .Stock going to 4.50-5
Norman Delore
Norman Delore Jun 02, 2025 11:37AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
that's short term. they got a patient until 2042. a calcium channel blocker nasal spray is s game changer.
Anthony Gautier
Anthony Gautier Apr 03, 2025 3:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Following the company’s announcement, HC Wainwright kept a ‘Buy’ rating on Milestone pharmaceuticals and noted that the FDA flagged no concerns around the efficacy of the product, thereby reaffirming the integrity of the clinical data. However, the firm expects the product's launch to be delayed until the first half of 2026.
Anthony Gautier
Anthony Gautier Apr 01, 2025 9:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The drug will get approved, just going through formality, company asked for a Class A review within 30 days...this will expedite the review and ruling.....jmo
Anthony Gautier
Anthony Gautier Mar 31, 2025 11:20AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buyer time
Anthony Gautier
Anthony Gautier Mar 31, 2025 9:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Within 30 days this will be on track
Anthony Gautier
Anthony Gautier Mar 29, 2025 4:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The Drug has proven effective and eventually will get approved after this inspection I believe, therefore hold and even adding 5k shares at this price level.....jmo
Anthony Gautier
Anthony Gautier Mar 28, 2025 2:57PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Eventually this drug WILL be approved...Great buying opportunity.....The FDA’s concerns did not pertain to the clinical safety or efficacy of etripamil but rather focused on additional information required on nitrosamine impurities and an inspection of a facility involved in release testing for the drug, which recently underwent a change in ownership. This facility inspection is necessary to ensure compliance with Current Good Manufacturing Practices.
Anthony Gautier
Anthony Gautier Mar 28, 2025 2:43PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The FDA is doing their job, with denying the drug, it's all precautionary measures that will cause a delay of a STILL promising drug. I think it's a great buying opportunity..Thanks please do your own due diligence and invest wisely
Anthony Gautier
Anthony Gautier Mar 28, 2025 2:38PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
analyst news, H.C. Wainwright maintained a Buy rating on Milestone, with a $25 price target, citing the potential approval of CARDAMYST by March 2025 as a significant driver. The firm highlighted the drug’s potential to transform the management of paroxysmal supraventricular tachycardia and its broader market opportunities.
Andrew Gordon
Andrew Gordon Mar 28, 2025 10:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$MIST I think that there will be a class action law suit. Why didn't management address the nitrosamine issue after the FDA guidance on nitrosamines in September? Why didn't management discuss the change of ownership of the manufacturer with the FDA?
Anthony Gautier
Anthony Gautier Mar 28, 2025 10:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Andrew Gordon, why can't you just calm down, there's no need to have a class action suit as this seems to only implicate a lack of follow through that was I'm sure unintentionally caused. The FDA is taking care of what's necessary without denying the product just the safety requirements which is the problem. I believe eventually this will be approved since it's a corrective measure that can be satisfied if any. Chill....patience is needed..
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email